このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Castle Biosciences 過去の業績

過去基準チェック /06

Castle Biosciencesの収益は年間平均-50.6%の割合で減少していますが、 Healthcare業界の収益は年間増加しています。収益は年間5.6% 36.2%割合で増加しています。

主要情報

-50.6%

収益成長率

-19.8%

EPS成長率

Healthcare 業界の成長	8.5%
収益成長率	36.2%
株主資本利益率	-7.7%
ネット・マージン	-12.3%
前回の決算情報	31 Mar 2024

Recent updates

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14

収支内訳

Castle Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:CSTL 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	251	-31	182	53
31 Dec 23	220	-57	180	54
30 Sep 23	192	-76	174	52
30 Jun 23	168	-89	168	50
31 Mar 23	152	-72	159	49
31 Dec 22	137	-67	143	45
30 Sep 22	124	-53	130	43
30 Jun 22	110	-44	114	40
31 Mar 22	98	-52	99	34
31 Dec 21	94	-31	87	30
30 Sep 21	86	-30	77	25
30 Jun 21	78	-23	66	20
31 Mar 21	68	-15	55	16
31 Dec 20	63	-10	48	13
30 Sep 20	63	-3	43	12
30 Jun 20	63	7	38	10
31 Mar 20	61	6	35	9
31 Dec 19	52	3	30	7
30 Sep 19	46	4	24	5
30 Jun 19	35	-6	21	5
31 Mar 19	28	-8	18	5
31 Dec 18	23	-10	16	5
31 Dec 17	41	-46	46	13

質の高い収益: CSTLは現在利益が出ていません。

利益率の向上: CSTLは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CSTLは利益が出ておらず、過去 5 年間で損失は年間50.6%の割合で増加しています。

成長の加速: CSTLの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CSTLは利益が出ていないため、過去 1 年間の収益成長をHealthcare業界 ( 15.1% ) と比較することは困難です。

株主資本利益率

高いROE: CSTLは現在利益が出ていないため、自己資本利益率 ( -7.65% ) はマイナスです。

Castle Biosciences 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test

Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology

Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM

Consensus estimates of losses per share improve by 28%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Founder notifies of intention to sell stock

Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress

Castle Biosciences, Inc. Announces Board Changes

Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test

Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 26%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Independent Chairman of the Board notifies of intention to sell stock

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2026

Founder exercised options and sold US$362k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder

Consensus estimates of losses per share improve by 21%

Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center

Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions

Consensus estimates of losses per share improve by 12%

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Independent Director recently bought US$69k worth of stock

Price target decreased by 11% to US$39.75

Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting

Consensus EPS estimates fall by 16%, revenue upgraded

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE

Castle Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Revises Revenue Guidance for the for Full-Year 2022

Founder exercised options and sold US$141k worth of stock

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Revenue Guidance for the Full Year 2022

過去基準チェック /06